Stocks · News reference

Morgan Stanley Maintains Overweight on Merck & Co, Lowers Price Target to $177

Oct 7, 2026, 2:50 PMBenzinga Newsdesk

Morgan Stanley analyst Terence Flynn maintains Merck & Co (NYSE:MRK) with a Overweight and lowers the price target from $179 to $177.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Oct 7, 2026, 2:50 PM
Checked: Oct 7, 2026, 2:50 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 7, 2026, 12:38 PMBenzinga News-desk
Halozyme Says Dutch Court Upholds Its Patent, Bars Merck From Making And Selling Keytruda SC In Multiple European Markets
HALO MRK
BenzingaOct 7, 2026, 12:35 PMBenzinga Newsdesk
Tempus Announces Expanded Collaboration With Merck And Moderna For Potential Commercialization Of Cancer Vaccine Intismeran Autogene; Terms Not Disclosed
MRK MRNA TEM
BenzingaOct 6, 2026, 4:27 AMMohd Haider
Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety
Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday. Moderna rose 0.17% to
MRK MRNA NVAX PCVX